Examining the Role of Neurobiology in Mental Health Disorders: Guidance for Managed Care on Treatment Targets and Benefit Design

Examining the Role of Neurobiology in Mental Health Disorders: Guidance for Managed Care on Treatment Targets and Benefit Design

On-Demand Webcast
Faculty

William J. Cardarelli, PharmD
Director of Pharmacy Revenue and Supply
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Joseph P. McEvoy, MD
Professor of Psychiatry and Health Behavior
Medical College of Georgia
Director of Public Psychiatry
Division of Behavioral Health and Developmental Disabilities
Augusta, Georgia

Michael Thase, MD
Professor of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participants should be able to:

  • Evaluate downstream clinical and economic consequences of nonadherence and treatment failure in MDD and schizophrenia
  • Describe common side effects associated with MDD and schizophrenia therapies and strategies for monitoring and mitigating them
  • Discuss the importance of neurobiology of MDD and schizophrenia, including the impact of receptor pharmacology on treatment efficacy and tolerability
  • Outline the safety, efficacy, and tolerability of newer MDD and schizophrenia treatment options
  • Apply recent clinical/cost data and individualized care strategies to formulary and patient access discussions for MDD and schizophrenia
Activity Overview

This on-demand webcast is available with synchronized slides and video.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Release Date: March 10, 2016
Expiration Date: March 10, 2017
Estimated time to complete: 1 hour

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This activity is approved for 1.0 contact hour (.1 CEUs) of continuing pharmacy education (UAN-0276-0000-16-055-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: William C. Torrey, MD, Professor and Vice Chair for Clinical Services, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire

Planning Committee

The planning committee comprises William J. Cardarelli, PharmD,  Joseph P. McEvoy, MD, Michael Thase, MD, William C. Torrey, MD; and Donna Brophy, Kristin Ciszeski, Mary Johnson, Michael Kearney, Susan Kuhn, Michelle Montgomery, Randy Robbin, John Savage, and Sydney Turner, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Dr. McEvoy: Grant/Research SupportAuspex, Alkermes, Avanir, Boehringer-Ingleheim, Otsuka; Scientific AdvisorNeurocrine, Otsuka

Dr. Thase: Advisory/ConsultantAlkermes, Allergan, AstraZeneca, Bristol-Myers Squibb Company, Cerecor, Inc., Eli Lilly & Co., Forest Laboratories, Gerson Lehrman Group, Fabre-Kramer Pharmaceuticals, Inc., GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Inc., Merck and Co, Inc., Moksha8, Maurex, Inc., Neuronetics, Inc., Novartis, Ortho-McNeil Pharmaceuticals, Otsuka, Pamlab, LLC., Pfizer, Shire US Inc., Sunovion Pharmaceuticals, Inc., Trius Therapeutical, Inc., Takeda; Grant Support—Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, National Institute of Mental Health, Otsuka Pharmaceuticals; Equity HoldingsMedAvante, Inc.; RoyaltiesAmerican Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.

Dr. Cardarelli and Dr. Torrey have disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Ms. Montgomery, Mr. Robbin, Mr. Savage and Ms. Turner have disclosed no relevant financial relationships with any commercial interests.

Ms. Kuhn: Stock Shareholder (spouse)—Osiris Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2016 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.